Allogene Therapeutics studies new 1L consolidation to prevent LBCL relapse

Traders Union
All News
Business & Wealth
Companies
Allogene tests new LBCL approach

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

10.07.2026

Allogene Therapeutics studies new 1L consolidation to prevent LBCL relapse — Allogene tests new LBCL approach

Allogene Therapeutics is investigating a novel first-line (1L) consolidation approach aimed at predicting and potentially preventing relapse in patients with large B-cell lymphoma (LBCL) following initial therapy.

The company has unveiled the ALPHA3 clinical trial, which could mark a significant step in the evolution of patient care for CAR-T and cell therapy applications. The trial focuses on allogeneic, or off-the-shelf, cell therapy as a consolidation strategy in the treatment pathway, highlighting innovation within the oncology landscape.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Allogene has previously outlined its aim to address limitations of autologous CAR T therapies through its investigational AlloCAR T platform. Early data from the ongoing ALPHA3 trial showed progress toward expanding access to off-the-shelf CAR T cell therapy for LBCL patients. The latest initiative builds on these efforts to widen treatment options in the field.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Allogene

Editor's Picks for You

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

By Pavlo Kot
10 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Editors' Picks

China’s crypto paradox: A booming market despite the ban?

By Alena Volkova
16 hours ago

China’s crypto paradox: A booming market despite the ban?

Editors' Picks

Global Microsoft outage: What happened and how serious is it?

By Mikhail Vnuchkov
Yesterday

Global Microsoft outage: What happened and how serious is it?

Editors' Picks

All Editors' Top Picks

Latest Allogene News

Allogene Therapeutics presents interim futility analysis for ALPHA3 at SITC2026

By Elena Nikulina
04.11.2026

Allogene Therapeutics presents interim futility analysis for ALPHA3 at SITC2026

Companies

Allogene Therapeutics advances early LBCL intervention with integrated ALPHA3 trial

By Mykhailo Ihnatenko
02.10.2026

Allogene Therapeutics advances early LBCL intervention with integrated ALPHA3 trial

Companies

Allogene Therapeutics to present pipeline and strategy updates at fall investor conferences

By Hlib Chabaniuk
01.09.2026

Allogene Therapeutics to present pipeline and strategy updates at fall investor conferences

Companies

All Allogene News

Pavlo Kot
10 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Alena Volkova
16 hours ago

China’s crypto paradox: A booming market despite the ban?

Mikhail Vnuchkov
Yesterday

Global Microsoft outage: What happened and how serious is it?

Dmytro Kharkov
Yesterday

Meme stocks vs. memecoins: Same viral frenzy, different endgames

Anastasiia Chabaniuk
12.11.2026

Better than Bitcoin? The coins that tried to dethrone the king

Pavlo Kot
30 min ago

David Gokhshtein: Anthropic seeks up to $64 billion in IPO, Bitcoin drops 18%

Eugene Komchuk
35 min ago

Craig Shapiro: Wall Street research examines AI unwind and funding outlook after midterms

Yaroslav Dmytrenko
40 min ago

Tom McClellan: NYSE Composite Index better comparison for A-D Line than S&P 500

Hanna Syniavska
45 min ago

U.S. inflation exceeds expectations, Bloomberg reports

Oksana Koneva
45 min ago

Stablecoin transfers on Tron settle nonstop as markets shift, Justin Sun notes

Top News

Jainam Mehta
2 hours ago

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Goldman Sachs forecasts 19% return for Asian stocks in 2027

Sholanke Dele
7 hours ago

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Oil prices fall nearly 25% in a month despite Iranian tanker attacks

Darina Pashchenko
7 hours ago

Bitcoin plunges below $67,000 as crypto liquidations reach $656 million

Bitcoin plunges below $67,000 as crypto liquidations reach $656 million

Pavlo Kot
10 hours ago

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Trustee Founder Vadym Hrusha: The future of crypto payments belongs to AI agents

Ivan Andriyenko
Yesterday

Bessent warns Fed against aggressive rate hikes amid energy shock

Bessent warns Fed against aggressive rate hikes amid energy shock

Top 5 companies for you

United States

Live News

Mykhailo Ihnatenko
Now

AMD stock faces profit-taking risk as AI momentum builds

Olga Shendetskaya
Now

Eurozone economy outperforms expectations, strengthening case for ECB rate hike

Anton Kharitonov
Now

EUR/USD remains under pressure as dollar strength threatens a drop to 1.1000

Mykhailo Ihnatenko
Now

Ethereum drops below $2,000: Can ETH recover amid $1.64 billion in crypto liquidations?

Pavlo Kot
Now

Indian authorities raid CoinDCX and Delta Exchange over suspicious crypto transactions

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.